




EMLc
ATC codes: [L01DB02](#)

Indication	Lymphoid leukaemia, NOS <span>ICD11 code: <a href="#">2C03.3</a></span>
INN	Daunorubicin
Medicine type	Chemical agent
List type	Complementary
Formulations	Parenteral > General injections > IV: 50 mg in vial (hydrochloride) powder for injection
EML status history	First added in 1999 ( <a href="#">TRS 895</a> ) Changed in 2002 ( <a href="#">TRS 914</a> ) Changed in 2007 ( <a href="#">TRS 950</a> ) Changed in 2015 ( <a href="#">TRS 994</a> )
Sex	All
Age	Also recommended for children
Therapeutic equivalence	The recommendation is for this specific medicine
Patent information	Patents have expired in most jurisdictions Read more <a href="#">about patents</a> . 

Tags
Cancer
Wikipedia
[Daunorubicin](#) 
DrugBank
[Daunorubicin](#) 

## Summary of evidence and Expert Committee recommendations

In 2015, as part of the comprehensive review of cancer medicines undertaken by the Expert Committee, listing for daunorubicin on the complementary list of the EML and EMLc for use in treatment protocols for acute lymphoblastic leukaemia was specifically endorsed. The relevant extract from TRS994 regarding the Expert Committee's 2015 consideration of treatment protocols for acute lymphoblastic leukaemia is attached.

Expert Committee report 
